Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Cancer Res Clin Oncol ; 148(4): 975-984, 2022 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-34143239

RESUMO

PURPOSE: The aim of this study is to assess international guidelines implementation concerning thromboprophylaxis strategy in myeloma patients treated with immunomodulatory drugs. METHODS: This retrospective study includes multiple myeloma patients treated with immunomodulatory drugs between 2014 and 2017 in the Hematology department of a teaching hospital (Hospices Civils de Lyon, France) and followed by the multidisciplinary care plan for cancer outpatients ONCORAL (ONCological care for outpatients with ORAL anticancer drugs). Data from immunomodulatory drugs administration, thromboprophylaxis strategy and thrombotic events were collected from medical files. Adherence to 2010 International Myeloma Working Group (IMWG) guidelines was assessed. RESULTS: 213 patients received at least one immunomodulatory drug: lenalidomide (60.9%), pomalidomide (24.0%) and thalidomide (15.1%). About two third of treatment lines (66.2%) were in accordance with IMWG recommendations. Among the others, 30.5% and 69.5% had thromboprophylaxis, respectively, superior or inferior to IMWG recommendations. 37 venous thrombotic events and 4 arterial thromboembolisms (one patient experienced both a stroke and deep venous thrombosis simultaneously) were reported. CONCLUSION: Thromboprophylaxis was systematically performed in myeloma patients treated with immunomodulatory drugs in this real-life retrospective cohort. However, the choice of anticoagulant or anti-platelet agent remains debatable, as adherence to existing guidelines was variable.


Assuntos
Mieloma Múltiplo , Tromboembolia Venosa , Anticoagulantes/uso terapêutico , Humanos , Fatores Imunológicos/uso terapêutico , Mieloma Múltiplo/complicações , Mieloma Múltiplo/tratamento farmacológico , Estudos Retrospectivos , Tromboembolia Venosa/etiologia , Tromboembolia Venosa/prevenção & controle
2.
Respir Med ; 95(10): 817-21, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11601748

RESUMO

Formoterol fumarate is a beta2-agonist bronchodilator that combines a fast onset of action with a long duration of action. Its fast onset of action is well documented in asthma but has not been directly compared with that of salbutamol in patients with chronic obstructive pulmonary disease (COPD). This randomized, double-blind, placebo-controlled study was conducted to assess the bronchodilatory effects over the first 3 h after inhalation of single doses of formoterol 24 microg delivered via the Aerolizer dry powder inhaler device (double-blind), or salbutamol 400 microg delivered by a Diskhaler dry powder inhaler (single-blind) in patients with COPD. A total of 24 patients with COPD were randomized [mean age 61.6 +/- 7.8 years, mean forced expiratory volume in 1 sec (FEV1) 1.38 +/- 0.32 l and 45.8 +/- 9.6% of predicted]. Inhalation of formoterol or salbutamol resulted in similar increases in FEV from 0 to 3 h post-dose. Both drugs produced similar bronchodilation by 5 min, which became almost maximal by 30 min. The primary efficacy variable, the area under the curve (AUC) of the FEV increase above predose baseline from 0 to 30 min (AUC(0-30 min)), demonstrated significant effects for formoterol (mean 5.89 +/- 4.67 l min(-1)), and salbutamol (mean 6.06 +/- 4.34 l min(-1)), which were not statistically different from each other but statistically significantly higher (P<0.0001) than that observed with placebo (-0.32 +/- 2.59 l min(-1)). In addition, both formoterol and salbutamol produced similar and rapid increases in forced vital capacity (FVC). In summary, this study confirms the rapid onset of action of formoterol and indicates that the onset of action of formoterol and salbutamol are similar in patients with COPD.


Assuntos
Albuterol/uso terapêutico , Broncodilatadores/uso terapêutico , Etanolaminas/uso terapêutico , Pneumopatias Obstrutivas/tratamento farmacológico , Pneumopatias Obstrutivas/fisiopatologia , Pulmão/fisiopatologia , Adulto , Aerossóis , Idoso , Área Sob a Curva , Estudos Cross-Over , Método Duplo-Cego , Feminino , Volume Expiratório Forçado , Fumarato de Formoterol , Humanos , Masculino , Pessoa de Meia-Idade , Placebos , Método Simples-Cego , Fumar/efeitos adversos , Fatores de Tempo , Capacidade Vital
3.
J Appl Microbiol ; 89(6): 944-50, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11123467

RESUMO

The influence of supplementing the culture medium with magnesium sulphate, D-glucose, L-cysteine, catalase or lithium chloride, of incubation temperature and of oxygen availability on the recovery of salt- or acid-damaged Listeria monocytogenes, was studied on a solid repair medium according to a Hadamard matrix, with seven parameters varying between a high and a low level. The most important factors for repair of stressed Listeria were further studied with complete factorial design experiments. Results show that conditions promoting resuscitation of acid- or salt-injured cells are stress-specific, and differ in part from those described in the literature for heat-stressed Listeria.


Assuntos
Listeria monocytogenes/fisiologia , Cloreto de Sódio/farmacologia , Anaerobiose , Catalase/farmacologia , Meios de Cultura , Cisteína/farmacologia , Glucose/farmacologia , Concentração de Íons de Hidrogênio , Listeria monocytogenes/efeitos dos fármacos , Listeria monocytogenes/crescimento & desenvolvimento , Cloreto de Lítio/farmacologia , Sulfato de Magnésio/farmacologia , Análise de Regressão , Temperatura
4.
Therapie ; 53(5): 429-37, 1998.
Artigo em Francês | MEDLINE | ID: mdl-9921034

RESUMO

Melatonin fulfils most of the requirements of a typical lead compound for rational drug design. We have rationally modified each of its structural features with a view to clarifying their role in drug-receptor interactions (affinity and activity) and to obtain agonist and antagonist ligands which could be used as pharmacological tools and/or as drugs. Molecular modelling studies allow us to propose a pharmacophore model. The naphthalenic bioisostere of melatonin (agomelatin) is currently under clinical (phase II) evaluation and two other compounds have been selected for development.


Assuntos
Melatonina/química , Acetamidas/química , Acetamidas/farmacologia , Animais , Benzofuranos/química , Benzofuranos/farmacologia , AMP Cíclico/biossíntese , Desenho de Fármacos , Técnicas In Vitro , Ligantes , Melatonina/agonistas , Melatonina/antagonistas & inibidores , Modelos Moleculares , Naftalenos/química , Naftalenos/farmacologia , Receptores de Superfície Celular/química , Receptores de Superfície Celular/efeitos dos fármacos , Receptores de Superfície Celular/metabolismo , Receptores Citoplasmáticos e Nucleares/química , Receptores Citoplasmáticos e Nucleares/efeitos dos fármacos , Receptores Citoplasmáticos e Nucleares/metabolismo , Receptores de Melatonina , Ovinos , Relação Estrutura-Atividade , Tetra-Hidronaftalenos/química , Tetra-Hidronaftalenos/farmacologia , Tiofenos/química , Tiofenos/farmacologia
5.
J Virol ; 69(11): 7309-14, 1995 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-7474160

RESUMO

In Epstein-Barr virus (EBV)-carrying nonproducer Raji cells, the induction of the viral replicative cycle by chemical treatment is limited to only the early stage and viral DNA synthesis is totally inhibited. We previously showed the absence of two messenger RNAs that are encoded by the BamHI-A fragment of the EBV genome and that correspond to open reading frames BALF2 and BARF1 in chemically induced Raji cells. Since the BALF2 gene encodes a 135-kDa DNA-binding protein which was immunoprecipitated by antibody against ICP8 protein, a key protein in herpes simplex virus replication, we asked whether the lack of productive cycle in Raji cells is due to the absence of expression of the BALF2 gene. We transfected the Raji cell line with the BALF2 gene. After chemical induction, the BALF2-transfected cells expressed not only early antigens but also late antigens. In these cultures, the viral particles were detected by electron microscopy. The expression of late antigens was completely inhibited by arabinofuranosylthymine, which is a specific inhibitor of viral DNA replication. The BALF2 gene might play an essential role in the induction of the EBV-lytic cycle.


Assuntos
Proteínas de Ligação a DNA/biossíntese , Expressão Gênica , Herpesvirus Humano 4/fisiologia , Fases de Leitura Aberta , Proteínas Virais/biossíntese , Replicação Viral , Antígenos Virais/biossíntese , Ciclo Celular , Divisão Celular , Linhagem Celular , Replicação do DNA , DNA Viral/biossíntese , Proteínas de Ligação a DNA/genética , Genes Virais , Genoma Viral , Herpesvirus Humano 4/genética , Humanos , Proteínas Recombinantes/biossíntese , Mapeamento por Restrição , Acetato de Tetradecanoilforbol/farmacologia , Transfecção , Células Tumorais Cultivadas , Proteínas Virais/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA